María Íñiguez , Patricia Pérez-Matute , Pablo Villoslada-Blanco , Emma Recio-Fernandez , Diana Ezquerro-Pérez , Jorge Alba , Concepción García-García , Galadriel Pellejero , M. Lourdes Ferreira-Laso , Dolores del Puerto García , Carlos Ruiz-Martínez , José A. Oteo
{"title":"Cardiotrophin-1 as a predictor of critical COVID-19, mortality, and persistence of pulmonary fibrosis after the acute phase of infection","authors":"María Íñiguez , Patricia Pérez-Matute , Pablo Villoslada-Blanco , Emma Recio-Fernandez , Diana Ezquerro-Pérez , Jorge Alba , Concepción García-García , Galadriel Pellejero , M. Lourdes Ferreira-Laso , Dolores del Puerto García , Carlos Ruiz-Martínez , José A. Oteo","doi":"10.1016/j.cyto.2025.157037","DOIUrl":null,"url":null,"abstract":"<div><div>Pulmonary fibrosis remains a long-term complication in some COVID-19 recovered patients, particularly in those who suffered from severe disease. Cardiotrophin-1 (CT-1) is an antiapoptotic cytokine related with the progression of fibrotic disease in heart and kidney. This study examines the association between CT-1 plasma levels, COVID-19 severity, and post-COVID pulmonary fibrosis. CT-1 levels were analyzed in patients with asymptomatic/mild (<em>n</em> = 33), severe (<em>n</em> = 39), and critical (<em>n</em> = 57) COVID-19, as well as in those with post-COVID pulmonary fibrosis. Elevated CT-1 levels were associated with a higher risk of severe disease, mortality, and persistent pulmonary fibrosis even a year after discharge. Furthermore, CT-1 was associated with non-COVID-19-related pulmonary fibrosis, suggesting a broader role of this cytokine in chronic lung diseases. These findings propose CT-1 as a potential biomarker and therapeutic target for pulmonary fibrosis and provide new insights for its role in chronic respiratory conditions, such as idiopathic pulmonary fibrosis (IPF), post-COVID interstitial lung disease or chronic hypersensitivity pneumonitis.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"196 ","pages":"Article 157037"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104346662500184X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary fibrosis remains a long-term complication in some COVID-19 recovered patients, particularly in those who suffered from severe disease. Cardiotrophin-1 (CT-1) is an antiapoptotic cytokine related with the progression of fibrotic disease in heart and kidney. This study examines the association between CT-1 plasma levels, COVID-19 severity, and post-COVID pulmonary fibrosis. CT-1 levels were analyzed in patients with asymptomatic/mild (n = 33), severe (n = 39), and critical (n = 57) COVID-19, as well as in those with post-COVID pulmonary fibrosis. Elevated CT-1 levels were associated with a higher risk of severe disease, mortality, and persistent pulmonary fibrosis even a year after discharge. Furthermore, CT-1 was associated with non-COVID-19-related pulmonary fibrosis, suggesting a broader role of this cytokine in chronic lung diseases. These findings propose CT-1 as a potential biomarker and therapeutic target for pulmonary fibrosis and provide new insights for its role in chronic respiratory conditions, such as idiopathic pulmonary fibrosis (IPF), post-COVID interstitial lung disease or chronic hypersensitivity pneumonitis.
期刊介绍:
The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
* Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors.
We will publish 3 major types of manuscripts:
1) Original manuscripts describing research results.
2) Basic and clinical reviews describing cytokine actions and regulation.
3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.